ResMed Inc. (RMD) is a publicly traded Healthcare sector company. As of July 8, 2026, RMD trades at $207.04 with a market cap of $31.68B and a P/E ratio of 20.95. RMD moved -5.60% today. Year to date, RMD is -9.60%; over the trailing twelve months it is -14.30%. Its 52-week range spans $180.27 to $293.81. Analyst consensus is buy with an average price target of $256.09. Rallies surfaces RMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ResMed to Sell MatrixCare for $490M, Named Top Momentum Stock: ResMed has agreed to sell its MatrixCare care-provider software suite to Frazier Healthcare Partners for $490 million in cash, with the transaction slated to close in the first quarter of fiscal 2027. Analyst style scores identify ResMed as a top momentum stock, highlighting its blend of value, growth and momentum attributes.
| Metric | Value |
|---|---|
| Price | $207.04 |
| Market Cap | $31.68B |
| P/E Ratio | 20.95 |
| EPS | $10.41 |
| Dividend Yield | 0.60% |
| 52-Week High | $293.81 |
| 52-Week Low | $180.27 |
| Volume | 988.88K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.54B |
| Net Income | $1.52B |
| Gross Margin | 61.59% |
14 analysts cover RMD: 0 strong buy, 8 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $256.09.